Mainz Biomed B.V. (MYNZ)
USD 2.85
(-4.53%)
USD 2.85
(-4.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 895.47 Thousand USD | 69.0% |
| 2022 | 529.87 Thousand USD | -8.22% |
| 2021 | 577.34 Thousand USD | 16.98% |
| 2020 | 493.56 Thousand USD | 75.4% |
| 2019 | 281.39 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q4 | 214.76 Thousand USD | 18.22% |
| 2023 Q1 | 250.1 Thousand USD | 29.4% |
| 2023 FY | 895.47 Thousand USD | 69.0% |
| 2023 Q2 | 248.94 Thousand USD | -0.46% |
| 2023 Q3 | 181.66 Thousand USD | -27.02% |
| 2022 Q4 | 193.28 Thousand USD | 99.69% |
| 2022 Q1 | 100.56 Thousand USD | -37.16% |
| 2022 Q3 | 96.79 Thousand USD | -30.49% |
| 2022 FY | 529.87 Thousand USD | -8.22% |
| 2022 Q2 | 139.24 Thousand USD | 38.46% |
| 2021 Q1 | 144.33 Thousand USD | 16.98% |
| 2021 FY | 577.34 Thousand USD | 16.98% |
| 2021 Q4 | 160.03 Thousand USD | 10.88% |
| 2021 Q3 | 144.33 Thousand USD | -65.41% |
| 2021 Q2 | 417.31 Thousand USD | 189.12% |
| 2020 Q1 | 123.39 Thousand USD | 75.4% |
| 2020 FY | 493.56 Thousand USD | 75.4% |
| 2020 Q4 | 123.39 Thousand USD | 0.0% |
| 2020 Q3 | 123.39 Thousand USD | 0.0% |
| 2020 Q2 | 123.39 Thousand USD | 0.0% |
| 2019 Q4 | 70.34 Thousand USD | 0.0% |
| 2019 FY | 281.39 Thousand USD | 0.0% |
| 2019 Q1 | 70.34 Thousand USD | 0.0% |
| 2019 Q2 | 70.34 Thousand USD | 0.0% |
| 2019 Q3 | 70.34 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 97.134% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | 93.301% |
| Aspira Women's Health Inc. | 9.15 Million USD | 90.218% |
| Biodesix, Inc. | 49.08 Million USD | 98.176% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | 90.835% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | 64.64% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | 64.64% |
| Bionano Genomics, Inc. | 36.11 Million USD | 97.521% |
| CareDx, Inc | 280.32 Million USD | 99.681% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | 99.593% |
| DarioHealth Corp. | 20.35 Million USD | 95.6% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.964% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 99.69% |
| Guardant Health, Inc. | 563.94 Million USD | 99.841% |
| ICON Public Limited Company | 8.12 Billion USD | 99.989% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.976% |
| Illumina, Inc. | 4.5 Billion USD | 99.98% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | 71.223% |
| iSpecimen Inc. | 9.92 Million USD | 90.98% |
| Standard BioTools Inc. | 106.34 Million USD | 99.158% |
| MDxHealth SA | 70.19 Million USD | 98.724% |
| 23andMe Holding Co. | 219.63 Million USD | 99.592% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 99.953% |
| Myriad Genetics, Inc. | 678.4 Million USD | 99.868% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| NeoGenomics, Inc. | 591.64 Million USD | 99.849% |
| Neogen Corporation | 924.22 Million USD | 99.903% |
| Inotiv, Inc. | 572.42 Million USD | 99.844% |
| Natera, Inc. | 1.08 Billion USD | 99.917% |
| OPKO Health, Inc. | 863.49 Million USD | 99.896% |
| Psychemedics Corporation | 22.09 Million USD | 95.948% |
| Prenetics Global Limited | 21.74 Million USD | 95.881% |
| Prenetics Global Limited | 21.74 Million USD | 95.881% |
| Precipio, Inc. | 15.19 Million USD | 94.108% |
| Personalis, Inc. | 73.48 Million USD | 98.781% |
| RadNet, Inc. | 1.61 Billion USD | 99.945% |
| Sera Prognostics, Inc. | 306 Thousand USD | -192.64% |
| Sotera Health Company | 1.04 Billion USD | 99.915% |
| Neuronetics, Inc. | 71.34 Million USD | 98.745% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 98.044% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 98.044% |
| Trinity Biotech plc | 56.83 Million USD | 98.424% |
| Twist Bioscience Corporation | 312.97 Million USD | 99.714% |
| Exagen Inc. | 52.54 Million USD | 98.296% |